What's next in general surgery — October 11, 2026

This edition covers what is coming in general surgery between mid-October 2026 and April 2027. We include only milestones with a verifiable date in an official or primary source; this time a single item meets that standard, and we would rather not pad the list. Off the list, we are tracking the 510(k) filings Medtronic submitted to the FDA on June 3, 2026 to expand the Hugo robotic system to general surgery (including hernia repair) and gynecology; we do not count them as an item because neither the FDA nor the company has given a decision date.
Source: https://news.medtronic.com/2026-06-03-Medtronic-submits-510-k-filings-to-expand-Hugo-TM-robotic-assisted-surgery-system-into-general-and-gynecologic-specialties-in-the-United-States

1. FDA decision on CagriSema for weight management

[Pending regulatory decision] [United States] [Estimated date: late 2026, per Novo Nordisk]
What it is: A once-weekly subcutaneous fixed-dose combination of cagrilintide (amylin analogue) 2.4 mg and semaglutide 2.4 mg. Novo Nordisk announced the submission of its New Drug Application to the FDA on December 18, 2025, based on the phase 3 REDEFINE 1 and REDEFINE 2 trials; in its February 23, 2026 announcement the company said it anticipates an FDA decision "by late 2026". No public PDUFA date exists.
What problem it solves: It widens the drug options for obesity, which may change who reaches the metabolic and bariatric surgery clinic and with how much weight already lost; and because both components slow gastric emptying, it adds one more agent to review in the preoperative assessment for elective and emergency surgery.
Critical take: In REDEFINE 4 (phase 3, open-label, 809 randomized adults with obesity, 84 weeks, sponsored by Novo Nordisk) it failed to demonstrate non-inferiority in weight loss versus tirzepatide 15 mg, its primary endpoint (23.0% vs 25.5% by the efficacy estimand; 20.2% vs 23.6% by the treatment-regimen estimand, regardless of adherence). These are sponsor-reported data; weight loss is an intermediate outcome, and US approval does not guarantee availability or an affordable price in our setting.
Source: https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916501
Source: https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916470

*What's next in general surgery — October 11, 2026*

This time, a single item with a verifiable date; we'd rather not pad.

• CagriSema (cagrilintide + semaglutide): FDA decision for weight management expected late 2026, per Novo Nordisk. Relevant to bariatric candidate selection and preoperative review (both components slow gastric emptying). Note: in REDEFINE 4 it did not demonstrate non-inferiority to tirzepatide.

Being tracked, no decision date: expansion of the Hugo robotic system to general surgery (including hernia repair) and gynecology (FDA filings of June 3, 2026).

Full text and audio: https://boletinesmedicos.com/en/general-surgery/2026-10-11-viene.html
Boletines Médicos · boletinesmedicos.com

What's next in general surgery (October 2026 – April 2027).

We only publish milestones with a verifiable date in an official source. This time a single item passed the filter:

CagriSema (cagrilintide + semaglutide), a once-weekly weight-management combination: Novo Nordisk expects the FDA decision in late 2026. It matters to surgeons for metabolic surgery candidate selection and for perioperative care, since both components slow gastric emptying. Critical take: in REDEFINE 4 it did not demonstrate non-inferiority to tirzepatide, and US approval does not ensure access in our setting.

We are also tracking Medtronic's filings to expand the Hugo robotic system to general surgery (including hernia repair) and gynecology, still without a decision date.

Full text and audio: https://boletinesmedicos.com/en/general-surgery/2026-10-11-viene.html

#GeneralSurgery #BariatricSurgery #Obesity #EvidenceBasedMedicine

What's next in general surgery: FDA decision on CagriSema expected late 2026, per Novo Nordisk (bariatric selection, perioperative care). One item with a verifiable date; we don't pad.
https://boletinesmedicos.com/en/general-surgery/2026-10-11-viene.html